- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:18 | Bullion Gold Resources Corp (2): Bullion Gold private placement | 2 | Stockwatch | ||
| Di | Bullion Gold Resources Corporation: High-Grade Gold up to 12.2 g/t Intersected in Multiple Structures at Bousquet | 391 | Newsfile | Montreal, Quebec--(Newsfile Corp. - January 6, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Corporation") is pleased to announce further assay results for the Bousquet... ► Artikel lesen | |
| 24.12.25 | Bullion Gold Resources Corp (2): Bullion Gold closes $300,000 private placement | 2 | Stockwatch | ||
| 23.12.25 | Bullion Gold Resources Corporation: Bullion Gold Completes Private Placement | 324 | Newsfile | Montreal, Quebec--(Newsfile Corp. - December 23, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Corporation") announces that it has closed a private placement (the "Offering")... ► Artikel lesen | |
| 02.12.25 | Bullion Gold Resources Corporation: Bullion Gold Presents the Historical Overview of Its Terragold Gold Project | 371 | Newsfile | Montreal, Quebec--(Newsfile Corp. - December 2, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or "the Corporation") will soon file an ATI permit application for a stripping and drilling... ► Artikel lesen | |
| BULLION GOLD RESOURCES Aktie jetzt für 0€ handeln | |||||
| 26.11.25 | Bullion Gold Resources Corporation: Bullion Gold Acquires the Transterre, Transterre-Ouest, and Candore Gold Projects (Forming the Terragold Project) | 424 | Newsfile | Montreal, Quebec--(Newsfile Corp. - November 26, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or "the Corporation") is pleased to announce the signing of an acquisition agreement... ► Artikel lesen | |
| 14.11.25 | Bullion Gold Resources Corp (2): Bullion begins survey at Langlade, appoints director | 1 | Stockwatch | ||
| 13.11.25 | Bullion Gold Resources Corporation: Bullion Gold Begins Geochemical Survey of Base Till on Langlade and Appoints a New Director to Its Board | 420 | Newsfile | Montreal, Quebec--(Newsfile Corp. - November 13, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or "The Company") is proud to announce the launch of an intensive follow-up program... ► Artikel lesen | |
| 29.10.25 | Bullion Gold Resources Corp (2): Bullion Gold private placement | 1 | Stockwatch | ||
| 28.10.25 | Bullion Gold Resources Corporation: 1.7km Gold System Emerging at Decoeur | 395 | Newsfile | Montreal, Quebec--(Newsfile Corp. - October 28, 2025) - Bullion Gold Resources (TSXV: BGD) ("Bullion Gold" or "The Company") is pleased to further assay results have been received for the Decoeur Prospect... ► Artikel lesen | |
| 22.10.25 | Bullion Gold Resources Corp (2): Bullion hires ITG as market-maker, arranges financing | 1 | Stockwatch | ||
| 21.10.25 | Bullion Gold Resources Corporation: Bullion Gold Engages Independent Trading Group as Market Maker, Announces Private Placement. | 1.039 | Newsfile | Montreal, Quebec--(Newsfile Corp. - October 21, 2025) - Bullion Gold Resources (TSXV: BGD) ("Bullion Gold" or "The Company") announces that, subject to regulatory approval, it has engaged the services... ► Artikel lesen | |
| 10.10.25 | Bullion Gold Resources Corp (2): Bullion Gold identifies Au grains at Cadillac-Extension | 1 | Stockwatch | ||
| 09.10.25 | Bullion Gold Resources Corporation: Bullion Gold Identifies Coarse, Irregular Gold Grains North of Langlade VMS Prospect (Cadillac-Extension Project), Launches Expanded Basal Till Sampling Program. | 288 | Newsfile | Montreal, Quebec--(Newsfile Corp. - October 9, 2025) - Bullion Gold Resources (TSXV: BGD) ("Bullion Gold" or "The Company") is pleased to announce encouraging preliminary results from a test basal... ► Artikel lesen | |
| 04.10.25 | Bullion Gold Resources Corp (2): Bullion Gold Resources private placement | 1 | Stockwatch | ||
| 02.10.25 | Bullion Gold Resources Corp (2): Bullion Gold's Canico samples return up to 2.16 g/t Au | 1 | Stockwatch | ||
| 02.10.25 | Bullion Gold Resources Corporation: Bullion Gold Confirms a Promising New Polymetallic Showing at Bodo and Identifies a Potential IOCG/SKARN-type Target | 427 | Newsfile | Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce the confirmation of the polymetallic character... ► Artikel lesen | |
| 30.09.25 | Bullion Gold Resources Corporation: Bousquet Drilling Demonstrates Down Dip Potential at Paquin | 331 | Newsfile | Montreal, Quebec--(Newsfile Corp. - September 30, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce that its partner Olympio Metals has just... ► Artikel lesen | |
| 17.09.25 | Bullion Gold Resources Corp (2): Bullion Gold sets out Quebec project exploration work | 1 | Stockwatch | ||
| 16.09.25 | Bullion Gold Resources Corporation: Bullion Gold Provides Updates on Its Bousquet, Langlade, and Bodo (Rivon Zone) Exploration Projects | 409 | Newsfile | Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to provide an update on the progress of its exploration... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 294,38 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| APOGEE THERAPEUTICS | 77,48 | -1,85 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,880 | +1,01 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,350 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,690 | -2,03 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,280 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 25,310 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,570 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,000 | 0,00 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| ALUMIS | 18,170 | 0,00 % | What's Going On With Alumis Stock Thursday? | ||
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 66,98 | +1,15 % | Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight | ||
| ERASCA | 5,840 | 0,00 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| RECURSION PHARMACEUTICALS | 4,700 | -3,29 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates |
BULLION GOLD RESOURCES CORPORATION gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BULLION GOLD RESOURCES CORPORATION finden Sie auf Wallstreet Online.